Vaishali Pharma Ltd.
NNSE:VAISHALI7.23
INR
-0.10
(-1.36%)
ISIN
INE972X01022
Return %
Stock
S&P 500
1Y
-29.87
14.20
3Y
-50.16
81.12
5Y
105.11
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Hemant Damodar Pathak
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 706 to 709, Aravalli Business Center Mumbai MA India 400092
- IPO Date
- Aug 22, 2017
- Website
- vaishalipharma.com
- Similar Companies
- Business
- Vaishali Pharma Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Its product portfolio includes a broad range of APIs such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet, skeletal muscle relaxants, and anti-helmintic drugs. The company also produces excipients, topical steroids, corticosteroids, enzymes, and a variety of nutraceuticals including dietary supplements, immunity boosters, probiotics, and other health supplements. Additionally, Vaishali Pharma offers formulations and surgical products and has an active presence in both domestic and international markets. The company is headquartered in Ahmedabad, India, and was founded in 1966. Recently, Vaishali Pharma formed a strategic partnership with Ahmedabad-based Sankalp LifeCare, a leading nutraceutical manufacturer, whereby Vaishali Pharma took over the domestic and international marketing operations for Sankalp LifeCare. This alliance marks a significant expansion into the nutraceutical sector, leveraging combined strengths for accelerated growth. In the most recent financial period, Vaishali Pharma reported notable growth in standalone net sales, exhibiting year-on-year increases of over 60% in some quarters in 2025, indicating strong operational performance. The company continues to emphasize quality certifications including WHO GMP, US FDA, ISO 9001:2015, HALAL, and FSSAI to support its product standards and global market presence. Vaishali Pharma operates primarily in the pharmaceutical industry segments of APIs, finished dosage formulations, herbal products, nutraceuticals, and surgical products. Its target markets include pharmaceutical companies, healthcare providers, and consumers of nutritional supplements across India and international regions where it exports its products. The company’s extensive product range features around 250 formulations tailored to different therapeutic categories and customer needs. Vaishali Pharma also offers contract manufacturing, regulatory support, research and development, and quality assurance services to pharmaceutical clients as part of its integrated business model. Overall, Vaishali Pharma Limited is a well-established pharmaceutical enterprise with a diverse product mix spanning traditional pharmaceuticals and emerging nutraceuticals, founded in 1966 and headquartered in Ahmedabad, India. Its recent strategic partnership with Sankalp LifeCare and ongoing sales growth underscore its expanding footprint and evolving market strategy in the pharmaceutical and health supplement sectors. Sources include the company website, recent financial reports, and industry news disclosures.